CA2401385A1 - Protein matrix materials, devices and methods of making and using thereof - Google Patents

Protein matrix materials, devices and methods of making and using thereof Download PDF

Info

Publication number
CA2401385A1
CA2401385A1 CA002401385A CA2401385A CA2401385A1 CA 2401385 A1 CA2401385 A1 CA 2401385A1 CA 002401385 A CA002401385 A CA 002401385A CA 2401385 A CA2401385 A CA 2401385A CA 2401385 A1 CA2401385 A1 CA 2401385A1
Authority
CA
Canada
Prior art keywords
agents
biocompatible
matrix material
protein matrix
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002401385A
Other languages
French (fr)
Other versions
CA2401385C (en
Inventor
David B. Masters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gel Del Technologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2401385A1 publication Critical patent/CA2401385A1/en
Application granted granted Critical
Publication of CA2401385C publication Critical patent/CA2401385C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/884—Preparations for artificial teeth, for filling teeth or for capping teeth comprising natural or synthetic resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

The present invention relates to protein matrix materials and devices and the methods of making and using protein matrix materials and devices. More specifically the present invention relates to protein matrix materials and devices that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, encapsulated or coated stent devices, vessels, tubular grafts, vascular grafts, wound healing devices including protein matrix suture material and meshes, skin/bone/tissue grafts, biocompatible electricity conducting matrices, clear protein matrices, protein matrix adhesion prevention barriers, cell scaffolding and other biocompatible protein matrix devices. Furthermore, the present invention relates to protein matrix materials and devices made by forming a film comprising one or more biodegradable protein materials, one or more biocompatible solvents and optionally one or more pharmacologically active agents. The film is then partially dried, rolled or otherwise shaped, and then compressed to form the desired protein matrix device.

Claims (140)

1. A protein matrix material comprising one or more biocompatible protein materials compressed with one or more biocompatible solvents to remove bulk solvent and form an interacting protein matrix material.
2. A protein matrix material comprising one or more biocompatible protein materials compressed with one or more biocompatible solvents to remove bulk solvent and form a matrix material wherein the compression of the protein material and the solvent material generates additional interactive forces.
3. The protein matrix material of claim 1 wherein the biocompatible proteins may be natural, synthetic or genetically engineered.
4. The protein matrix material of claim 3 wherein the biocompatible proteins is a natural protein selected from the group consisting of elastin, collagen, albumin, keratin, fibronectin, silk, silk fibroin, actin, myosin, fibrinogen, thrombin, aprotinin and antithrombin III.
5. The protein matrix material of claim 1 wherein the biocompatible proteins is a genetically engineered protein made of blocks selected from the group consisting of elastinlike blocks, silklike blocks, collagenlike blocks, lamininlike blocks, fibronectinlike blocks and silklike and elastinlike blocks.
6. The protein matrix material of claim 1 wherein the biocompatible solvent is selected from the group consisting of water, dimethyl sulfoxide (DMSO), biocompatible alcohols, biocompatible acids, oils and biocompatible glycols.
7. The protein matrix material of claim 6 wherein the biocompatible solvent is water.
8. The protein matrix material of claim 1 further comprising one or more pharmacologically active agents.
9. The protein matrix material of claim 8 wherein the one or more pharmacologically active agents are selected from the group consisting of analgesics, anesthetics, antipsychotic agents, steroids, antisteroids, corticosteroids, antiglacoma agents, antialcohol agents, anti-coagulants agents, genetic material, antithrombolytic agents, anticancer agents, anti-Parkinson agents, antiepileptic agents, anti-inflammatory agents, anticonception agents, enzymes agents, cells, growth factors, antiviral agents, antibacterial agents, antifungal agents, hypoglycemic agents, antihistamine agents, chemoattractants, neutraceuticals, antiobesity, smoking cessation agents, obstetric agents and antiasmatic agents.
10. The method of claim 8, wherein the pharmacologically active agent comprises a second, migration-vulnerable drug delivery device.
11. The method of claim 10, wherein the migration-vulnerable drug delivery device comprises a plurality of lipospheres homogeneously dispersed within the drug delivery device.
12. The method of claim 8, wherein the migration-vulnerable drug delivery device comprises a plurality of microspheres homogeneously dispersed within the protein matrix material.
13. The method of claim 1, wherein the pharmacologically active agent is substantially homogeneously distributed within the protein matrix material.
14. The protein matrix material of claim 1 further comprising one or more biocompatible polymeric materials.
15. The protein matrix material of claim 8 further comprising one or more biocompatible polymeric materials.
16. The protein matrix material of claim 1 wherein the one or more biocompatible polymeric materials are selected from the group consisting of epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, polyurethane, polycarbonate, poly(tetrafluoroethylene), polycaprolactone, polyethylene oxide, polyethylene glycol, polyvinyl chloride), polylactic acid, polyglycolic acid, polypropylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol, 2-hydroxyethyl methacrylate, polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxybutyrate, polyhydroxyvalerate, polyethylene oxide), poly ortho esters, poly (amino acids), polycynoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl-based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, and copolymers of these.
17. The protein matrix material of claim 8 wherein the one or more biocompatible polymeric materials are selected from the group consisting of epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, polyurethane, polycarbonate, poly(tetrafluoroethylene), polycaprolactone, polyethylene oxide, polyethylene glycol, polyvinyl chloride), polylactic acid, polyglycolic acid, polypropylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol, 2-hydroxyethyl methacrylate, polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxybutyrate, polyhydroxyvalerate, polyethylene oxide), poly ortho esters, poly (amino acids), polycynoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl-based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, and copolymers of these.
18. The protein matrix material of claim 1 wherein the protein matrix material is crosslinked with one or more crosslinking agents.
a
19. The protein matrix material of claim 8 wherein the protein matrix material is crosslinked with one or more crosslinking agents.
20. The protein matrix material of claim 18 wherein the one or more crosslinking reagents are selected from the group consisting of glutaraldehyde, p-Azidobenzolyl Hydazide, N-5-Azido-2-nitrobenzoyloxysuccinimide, N-Succinimidyl 6-[4'azido-2'nitro-phenylamino]hexanoate and 4-[p-Azidosalicylamido] butylamine.
21. The protein matrix material of claim 19 wherein the one or more crosslinking reagents are selected from the group consisting of glutaraldehyde, p-Azidobenzolyl Hydazide, N-5-Azido-2-nitrobenzoyloxysuccinimide, N-Succinimidyl 6-[4'azido-2'nitro-phenylamino]hexanoate and 4-[p-Azidosalicylamido] butylamine.
22. A protein matrix material comprising one or more biocompatible protein materials and one or more biocompatible solvents made by the steps comprising:

(a) preparing a coatable composition including the one or more biocompatible protein materials, and the one or more biocompatible solvents;
(b) coating the composition to form a film;
(c) partially drying the coated film until the coated film can be formed into a cohesive body;
(d) forming said cohesive body; and compressing the cohesive body to form a protein matrix material
23. The protein matrix material of claim 22 wherein the biocompatible proteins may be natural, synthetic or genetically engineered.
24. The protein matrix material of claim 22 wherein the biocompatible proteins is a natural protein selected from the group consisting of elastin, collagen, albumin, keratin, fibronectin, silk, silk fibroin, actin, myosin, fibrinogen, thrombin, aprotinin and antithrombin III.
25. The protein matrix material of claim 23 wherein the biocompatible proteins are genetically engineered proteins made of blocks selected from the group consisting of elastinlike blocks, silklike blocks, collagenlike blocks, lamininlike blocks, fibronectinlike blocks and silklike and elastinlike blocks.
26. The protein matrix material of claim 22 wherein the biocompatible solvent is selected from the group consisting of water, dimethyl sulfoxide (DMSO), biocompatible alcohols, biocompatible acids, oils and biocompatible glycols.
27. The protein matrix material of claim 26 wherein the biocompatible solvent is water.
28. The protein matrix material of claim 22 further comprising one or more pharmacologically active agents.
29. The protein matrix material of claim 28 wherein the one or more pharmacologically active agents are selected from the group consisting of analgesics, anesthetics, anti psychotic agents, steroids, antisteroids, corticosteroids, antiglacoma agents, antialcohol agents, anti-coagulants agents, genetic material, antithrombolytic agents, anticancer agents, anti-Parkinson agents, antiepileptic agents, anti-inflammatory agents, anticonception agents, enzymes agents, cells, growth factors, antiviral agents, antibacterial agents, antifungal agents, hypoglycemic agents, antihistamine agents, chemoattractants, neutraceuticals, antiobesity, smoking cessation agents and antiasmatic agents.
30. The protein matrix material of claim 28, wherein the pharmacologically active agent comprises a second, migration-vulnerable drug delivery device.
31. The protein matrix material of claim 30, wherein the migration-vulnerable drug delivery device comprises a plurality of lipospheres homogeneously dispersed within the protein matrix material.
32. The protein matrix material of claim 28, wherein the migration-vulnerable drug delivery device comprises a plurality of microspheres homogeneously dispersed within the protein matrix material.
33. The protein matrix material of claim 28, wherein the pharmacologically active agent is substantially homogeneously distributed within the protein matrix material.
34. The protein matrix material of claim 22 further comprising one or more biocompatible polymeric materials.
35. The protein matrix material of claim 28 further comprising one or more biocompatible polymeric materials.
36. The protein matrix material of claim 34 wherein the one or more biocompatible polymeric materials are selected from the group consisting of epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, polyurethane, polycarbonate, poly(tetrafluoroethylene), polycaprolactone, polyethylene oxide, polyethylene glycol, poly(vinyl chloride), polylactic acid, polyglycolic acid, polypropylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol, 2-hydroxyethyl methacrylate, polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxybutyrate, polyhydroxyvalerate, poly(ethylene oxide), poly ortho esters, poly(amino acids), polycynoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl-based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, and copolymers of these.
37. The protein matrix material of claim 28 wherein the one or more biocompatible polymeric materials are selected from the group consisting of epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, polyurethane, polycarbonate, poly(tetrafluoroethylene), polycaprolactone, polyethylene oxide, polyethylene glycol, poly(vinyl chloride), polylactic acid, polyglycolic acid, polypropylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol, 2-hydroxyethyl methacrylate, polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxybutyrate, polyhydroxyvalerate, poly(ethylene oxide), poly orthoesters, poly (amino acids), polycynoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl-based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, and copolymers of these.
38. The protein matrix material of claim 22 wherein the protein matrix material is crosslinked with one or more crosslinking agents.
39. The protein matrix material of claim 28 wherein the protein matrix material is crosslinked with one or more crosslinking agents.
40. The protein matrix material of claim 38 wherein the crosslinking agents are selected from the group consisting of glutaraldehyde, p-Azidobenzolyl Hydazide, N-5-Azido-2-nitrobenzoyloxysuccinimide, N-Succinimidyl 6-[4'azido-2'nitro-phenylamino]hexanoate and 4-[p-Azidosalicylamido] butylamine.
41. The protein matrix material of claim 39 wherein the one or more crosslinking reagents are selected from the group consisting of glutaraldehyde, p-Azidobenzolyl Hydazide, N-5-Azido-2-nitrobenzoyloxysuccinimide, N-Succinimidyl 6-[4'azido-2'nitro-phenylamino]hexanoate and 4-[p-Azidosalicylamido] butylamine.
42. A method of making a protein matrix material, comprising the steps of (a) preparing a coatable composition comprising one or more biocompatible protein materials and one or more biocompatible solvents;
(b) coating the composition to form a film;
(c) partially drying the coated film until the coated film can be formed into a cohesive body;
(d) forming said cohesive body; and compressing the cohesive body to form a protein matrix material.
43. The method of making a protein matrix material of claim 42 wherein the biocompatible proteins may be natural, synthetic or genetically engineered.
44. The method of making a protein matrix material of claim 43 wherein the biocompatible proteins is a natural protein selected from the group consisting of elastin, collagen, albumin, keratin, fibronectin, silk, silk fibroin, actin, myosin, fibrinogen, thrombin, aprotinin and antithrombin III.
45. The method of making a protein matrix material of claim 43 wherein the biocompatible proteins is a genetically engineered protein made of blocks selected from the group consisting of elastinlike blocks, silklike blocks, collagenlike blocks, lamininlike blocks, fibronectinlike blocks and silklike and elastinlike blocks.
46. The method of making a protein matrix material of claim 42 wherein. the biocompatible solvent is selected from the group consisting of water, dimethyl sulfoxide (DMSO), biocornpatible alcohols, biocompatible acids, oils and biocompatible glycols.
47. The method of making a protein matrix material of claim 46 wherein the biocompatible solvent is water.
48. The method of making a protein matrix material of claim 42 further comprising one or more pharmacologically active agents.
49. The method of making a protein matrix material of claim 48 wherein the one or more pharmacologically active agents are selected from the group consisting of analgesics, anesthetics, antipsychotic agents, steroids, antisteroids, corticosteroids, antiglacoma agents, antialcohol agents, anti-coagulants agents, genetic material, antithrombolytic agents, anticancer agents, anti-Parkinson agents, antiepileptic agents, anti-inflammatory agents, anticonception agents, enzymes agents, cells, growth factors, antiviral agents, antibacterial agents, antifungal agents, hypoglycemic agents, antihistamine agents, chemoattractants, neutraceuticals, antiobesity, smoking cessation agents, obstetric agents and antiasmatic agents.
50. The method of making a protein matrix material of claim 48, wherein the pharmacologically active agent comprises a second, migration-vulnerable drug delivery device.
51. The method of making a protein matrix material of claim 50, wherein the migration-vulnerable drug delivery device comprises a plurality of lipospheres homogeneously dispersed within the drug delivery device.
52. The method of making a protein matrix material of claim 48, wherein the migration-vulnerable drug delivery device comprises a plurality of microspheres homogeneously dispersed within the protein matrix material.
53. The method of making a protein matrix material of claim 42, wherein the pharmacologically active agent is substantially homogeneously distributed within the protein matrix material.
54. The method of making a protein matrix material of claim 1 further comprising one or more biocompatible polymeric materials.
55. The method of making a protein matrix material of claim 48 further comprising one or more biocompatible polymeric materials.
56. The method of making a protein matrix material of claim 42 further comprising the step of crosslinking the protein matrix material with a suitable crosslinking agent.
57. The method of making a protein matrix material of claim 48 further comprising the step of crosslinking the protein matrix material with a suitable crosslinking agent.
58. A drug delivery device comprising one or more biocompatible protein materials compressed with one or more pharmacologically active agents and one or more biocompatible solvents to remove bulk solvent and form an interacting drug delivery device.
59. A drug delivery device comprising one or more biocompatible protein materials compressed with one or more pharmacologically active agents and one or more biocompatible solvents to remove bulk solvent and form a drug delivery device wherein the compression of the protein material and the pharmacologically active agents and solvent material generates additional interactive forces.
60. The drug delivery device of claim 58 wherein the biocompatible proteins may be natural, synthetic or genetically engineered.
61. The drug delivery device of claim 60 wherein the biocompatible proteins is a natural protein selected from the group consisting of elastin, collagen, albumin, keratin, fibronectin, silk, silk fibroin, actin, myosin, fibrinogen, thrombin, aprotinin and antithrombin III.
62. The drug delivery device of claim 60 wherein the biocompatible proteins is a genetically engineered protein made of blocks selected from the group consisting of elastinlike blocks, silklike blocks, collagenlike blocks, lamininlike blocks, fibronectinlike blocks and silklike and elastinlike blocks.
63. The drug delivery device of claim 58 wherein the biocompatible solvent is selected from the group consisting of water, dimethyl sulfoxide (DMSO), biocompatible alcohols, biocompatible acids, oils and biocompatible glycols.
64. The drug delivery device of claim 63 wherein the biocompatible solvent is water.
65. The drug delivery device of claim 58 wherein the one or more pharmacologically active agents are selected from the group consisting of analgesics, anesthetics, antipsychotic agents, steroids, antisteroids, corticosteroids, antiglacoma agents, antialcohol agents, anti-coagulants agents, genetic material, antithrombolytic agents, anticancer agents, anti-Parkinson agents, antiepileptic agents, anti-inflammatory agents, anticonception agents, enzymes agents, cells, growth factors, antiviral agents, antibacterial agents, antifungal agents, hypoglycemic agents, antihistamine agents, chemoattractants, neutraceuticals, antiobesity, smoking cessation agents, obstetric agents and antiasmatic agents.
66. The drug delivery device of claim 58, wherein the pharmacologically active agent comprises a second, migration-vulnerable drug delivery device.
67. The drug delivery device of claim 66, wherein the migration-vulnerable drug delivery device comprises a plurality of lipospheres homogeneously dispersed within the drug delivery device.
68. The drug delivery device of claim 66, wherein the migration-vulnerable drug delivery device comprises a plurality of microspheres homogeneously dispersed within the protein matrix material.
69. The drug delivery device of claim 58, wherein the pharmacologically active agent is substantially homogeneously distributed within the protein matrix material.
70. The drug delivery device of claim 58 further comprising one or more biocompatible polymeric materials.
71. The drug delivery device of claim 58 wherein the drug delivery device is crosslinked with one or more crosslinking agents.
72. The drug delivery device of claim 58 wherein the drug delivery device is produced in particulate form.
73. The drug delivery device of claim 58 wherein the pharmacologically active agents are selected from the group consisting of analgesics, anesthetics, antipsychotic agents, steroids, antisteroids, corticosteroids, antiglacoma agents, antialcohol agents, anti-coagulants agents, genetic material, antithrombolytic agents, anticancer agents, anti-Parkinson agents, antiepileptic agents, anti-inflammatory agents, anticonception agents, enzymes agents, cells, growth factors, antiviral agents, antibacterial agents, antifungal agents, hypoglycemic agents, antihistamine agents, chemoattractants, neutraceuticals, antiobesity, smoking cessation agents, obstetric agents and antiasmatic agents.
74. The drug delivery device of claim 72 wherein the pharmacologically active agents are selected from the group consisting of analgesics, anesthetics, antipsychotic agents, steroids, antisteroids, corticosteroids, antiglacoma agents, antialcohol agents, anti-coagulants agents, genetic material, antithrombolytic agents, anticancer agents, anti-Parkinson agents, antiepileptic agents, anti-inflammatory agents, anticonception agents, enzymes agents, cells, growth factors, antiviral agents, antibacterial agents, antifungal agents, hypoglycemic agents, antihistamine agents, chemoattractants, neutraceuticals, antiobesity, smoking cessation agents, obstetric agents and antiasmatic agents.
75. A wound healing device comprising one or more biocompatible protein materials compressed with one or more biocompatible solvents to remove bulk solvent and form an interacting wound healing device.
76. A wound healing device comprising one or more biocompatible protein materials compressed with one or more biocompatible solvents to remove bulk solvent and form a wound healing device wherein the compression of the protein material and the solvent material generates additional interactive forces.
77. The wound healing device of claim 75 wherein the biocompatible proteins may be natural, synthetic or genetically engineered.
78. The wound healing device of claim 75 wherein the biocompatible proteins are natural proteins selected from the group consisting of elastin, collagen, albumin, keratin, f bronectin, silk, silk fibroin, actin, myosin, fibrinogen, thrombin, aprotinin and antithrombin III.
79. The wound healing device of claim 75 wherein the biocompatible proteins are genetically engineered proteins made of blocks selected from the group consisting of elastinlike blocks, silklike blocks, collagenlike blocks, lamininlike blocks, fibronectinlike blocks and silklike and elastinlike blocks.
80. The wound healing device of claim 75 wherein the biocompatible solvent is selected from the group consisting of water, dimethyl sulfoxide (DMSO), biocompatible alcohols, biocompatible acids, oils and biocompatible glycols.
81. The wound healing device of claim 80 wherein the biocompatible solvent is water.
82. The wound healing device of claim 75 further comprising one or more pharmacologically active agents.
83. The wound healing device of claim 82 wherein the one or more pharmacologically active agents are selected from the group consisting of analgesics, anesthetics, antipsychotic agents, steroids, antisteroids, corticosteroids, antiglacoma agents, antialcohol agents, anti-coagulants agents, genetic material, antithrombolytic agents, anticancer agents, anti-Parkinson agents, antiepileptic agents, anti-inflammatory agents, anticonception agents, enzymes agents, cells, growth factors, antiviral agents, antibacterial agents, antifungal agents, hypoglycemic agents, antihistamine agents, chemoattractants, neutraceuticals, antiobesity, smoking cessation agents, obstetric agents and antiasmatic agents.
84. The wound healing device of claim 82, wherein the pharmacologically active agent comprises a second, migration-vulnerable drug delivery device.
85. The wound healing device of claim 84, wherein the migration-vulnerable drug delivery device comprises a plurality of lipospheres homogeneously dispersed within the drug delivery device.
86. The wound healing device of claim 84, wherein the migration-vulnerable drug delivery device comprises a plurality of microspheres homogeneously dispersed within the protein matrix material.
87. The wound healing device of claim 75 further comprising one or more biocompatible polymeric materials.
88. The wound healing device of claim 82 further comprising one or more biocompatible polymeric materials.
89. The wound healing device of claim 87 wherein the one or more biocompatible polymeric materials are selected from the group consisting of epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, polyurethane, polycarbonate, poly(tetrafluoroethylene), polycaprolactone, polyethylene oxide, polyethylene glycol, poly(vinyl chloride), polylactic acid, polyglycolic acid, polypropylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol, 2-hydroxyethyl methacrylate, polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxybutyrate, polyhydroxyvalerate, polyethylene oxide), poly ortho esters, poly (amino acids), polycynoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl-based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, and copolymers of these.
90. The wound healing device of claim 88 wherein the one or more biocompatible polymeric materials are selected from the group consisting of epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, polyurethane, polycarbonate, poly(tetrafluoroethylene), polycaprolactone, polyethylene oxide, polyethylene glycol, poly(vinyl chloride), polylactic acid, polyglycolic acid, polypropylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol, 2-hydroxyethyl methacrylate, polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxybutyrate, polyhydroxyvalerate, poly(ethylene oxide), poly ortho esters, poly (amino acids), polycynoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl-based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, and copolymers of these.
91. The wound healing device of claim 75 wherein the wound healing device is crosslinked with one or more crosslinking agents.
92. The wound healing device of claim 82 wherein the wound healing device is crosslinked with one or more crosslinking agents.
93. The wound healing device of claim 75 wherein the wound healing device is selected from the group consisting of bone inserts, meshes, strips, sutures, dental plugs, skin dressings, bandages, tissue plugs, vertebrae inserts, vertebral discs, joints, bronchial tissue inserts, abdominal inserts, vascular inserts and port seals.
94 The wound healing device of claim 82 wherein the bandage comprises a segment of protein matrix material positioned on a non-adhesive strip adjoined to adhesive ends.
95. The wound healing device of claim 82 wherein the wound healing device includes a patch delivery system adjoined behind the protein matrix dressing for delivery of additional pharmacologically active agents.
96. A tissue graft comprising one or more biocompatible protein materials compressed with one or more biocompatible solvents to remove bulk solvent and form an interacting tissue graft.
97. A tissue graft comprising one or more biocompatible protein materials compressed with one or more biocompatible solvents to remove bulk solvent and form a tissue graft wherein the compression of the protein material and the solvent material generates additional interactive forces.
98. The tissue graft of claim 96 wherein the biocompatible proteins may be natural, synthetic or genetically engineered.
99. The tissue graft of claim 97 wherein the biocompatible proteins are natural proteins selected from the group consisting of elastin, collagen, albumin, keratin, fibronectin, silk, silk fibroin, actin, myosin, fibrinogen, thrombin, aprotinin and antithrombin III.
100. The tissue graft of claim 96 wherein the biocompatible proteins are genetically engineered proteins made of blocks selected from the group consisting of elastinlike blocks, silklike blocks, collagenlike blocks, lamininlike blocks, fibronectinlike blocks and silklike and elastinlike blocks.
101. The tissue graft of claim 96 wherein the biocompatible solvent is selected from the group consisting of water, dimethyl sulfoxide (DMSO), biocompatible alcohols, biocompatible acids, oils and biocompatible glycols.
102. The tissue graft of claim 101 wherein the biocompatible solvent is water.
103. The tissue graft of claim 96 further comprising one or more pharmacologically active agents.
104. The tissue graft of claim 103 wherein the one or more pharmacologically active agents are selected from the group consisting of analgesics, anesthetics, antipsychotic agents, steroids, antisteroids, corticosteroids, antiglacoma agents, antialcohol agents, anti-coagulants agents, genetic material, antithrombolytic agents, anticancer agents, anti-Parkinson agents, antiepileptic agents, anti-inflammatory agents, anticonception agents, enzymes agents, cells, growth factors, antiviral agents, antibacterial agents, antifungal agents, hypoglycemic agents, antihistamine agents, chemoattractants, neutraceuticals, antiobesity, smoking cessation agents, obstetric agents and antiasmatic agents.
105. The tissue graft of claim 103, wherein the pharmacologically active agent comprises a second, migration-vulnerable drug delivery device.
106. The tissue graft of claim 105, wherein the migration-vulnerable drug delivery device comprises a plurality of lipospheres homogeneously dispersed within the drug delivery device.
107. The tissue graft of claim 105, wherein the migration-vulnerable drug delivery device comprises a plurality of microspheres homogeneously dispersed within the protein matrix material.
108. The tissue graft of claim 96 further comprising one or more biocompatible polymeric materials.
109. The tissue graft of claim 103 further comprising one or more biocompatible polymeric materials.
110. The tissue graft of claim 108 wherein the one or more biocompatible polymeric materials are selected from the group consisting of epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, polyurethane, polycarbonate, poly(tetrafluoroethylene), polycaprolactone, polyethylene oxide, polyethylene glycol, poly(vinyl chloride), polylactic acid, polyglycolic acid, polypropylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol, 2-hydroxyethyl methacrylate, polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxybutyrate, polyhydroxyvalerate, poly(ethylene oxide), poly ortho esters, poly (amino acids), polycynoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl-based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, and copolymers of these.
111. The tissue graft of claim 109 wherein the one or more biocompatible polymeric materials are selected from the group consisting of epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, polyurethane, polycarbonate, poly(tetrafluoroethylene), polycaprolactone, polyethylene oxide, polyethylene glycol, polyvinyl chloride), polylaetic acid, polyglycolic acid, polypropylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol, 2-hydroxyethyl methacrylate, polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxybutyrate, polyhydroxyvalerate, polyethylene oxide), poly ortho esters, poly (amino acids), polycynoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl-based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, and copolymers of these.
112. The tissue graft of claim 96 wherein the tissue graft is crosslinked with one or more crosslinking agents.
113. The tissue graft of claim 103 wherein the tissue graft is crosslinked with one or more crosslinking agents.
114. The tissue graft of claim 96 wherein the tissue graft are selected from the group consisting of vessels, tubular grafts, tracheal tubes, bronchial tubes, catheter functioning tubes, lung grafts, gastrointestinal segments; clear matrix grafts; heart valves;
cartilage; tendons;
ligaments, skin grafts and pancreatic implant devices.
115. The tissue graft of claim 103 wherein the tissue graft are selected from the group consisting of vessels, tubular grafts, tracheal tubes, bronchial tubes, catheter functioning tubes, lung grafts, gastrointestinal segments; clear matrix grafts; heart valves;
cartilage; tendons;
ligaments, skin grafts and pancreatic implant devices.
116. The wound healing device of claim 83 wherein the wound healing device is selected from the group consisting of bone inserts, meshes, strips, sutures, dental plugs, skin dressings, bandages, tissue plugs, vertebrae inserts, vertebral discs, joints, bronchial tissue inserts, abdominal inserts, vascular inserts and port seals.
117. An encapsulated or coated stent device comprising one or more biocompatible protein materials compressed with one or more biocompatible solvents to remove bulk solvent and form an interacting encapsulated or coated stent device.
118. An encapsulated or coated stent device comprising one or more biocompatible protein materials compressed with one or more biocompatible solvents to remove bulk solvent and form a encapsulated or coated stent device wherein the compression of the protein material and the solvent material generates additional interactive forces.
119. The encapsulated or coated stent device of claim 116 wherein the biocompatible proteins may be natural, synthetic or genetically engineered.
120. The encapsulated or coated stent device of claim 118 wherein the biocompatible proteins are natural proteins selected from the group consisting of elastin, collagen, albumin, keratin, fibronectin, silk, silk fibroin, actin, myosin, fibrinogen, thrombin, aprotinin and antithrombin III.
121. The encapsulated or coated stent device of claim 116 wherein the biocompatible proteins are genetically engineered proteins made of blocks selected from the group consisting of elastinlike blocks, silklike blocks, collagenlike blocks, lamininlike blocks, fibronectinlike blocks and silklike and elastinlike blocks.
122. The encapsulated or coated stent device of claim 116 wherein the biocompatible solvent is selected from the group consisting of water, dimethyl sulfoxide (DMSO), biocompatible alcohols, biocompatible acids, oils and biocompatible glycols.
123. The encapsulated or coated stent device of claim 121 wherein the biocompatible solvent is water.
124. The encapsulated or coated stent device of claim 116 further comprising one or more pharmacologically active agents.
125. The encapsulated or coated stent device of claim 123 wherein the one or more pharmacologically active agents are selected from the group consisting of analgesics, anesthetics, antipsychotic agents, steroids, antisteroids, corticosteroids, antiglacorna agents, antialcohol agents, anti-coagulants agents, genetic material, antithrombolytic agents, anticancer agents, anti-Parkinson agents, antiepileptic agents, anti-inflammatory agents, anticonception agents, enzymes agents, cells, growth factors, antiviral agents, antibacterial agents, antifungal agents, hypoglycemic agents, antihistamine agents, chemoattractants, neutraceuticals, antiobesity, smoking cessation agents, obstetric agents and antiasmatic agents.
126. The encapsulated or coated stent device of claim 123, wherein the pharmacologically active agent comprises a second, migration-vulnerable drug delivery device.
127. The encapsulated or coated stent device of claim 125, wherein the migration-vulnerable drug delivery device comprises a plurality of lipospheres homogeneously dispersed within the drug delivery device.
128. The encapsulated or coated stent device of claim 125, wherein the migration-vulnerable drug delivery device comprises a plurality of microspheres homogeneously dispersed within the protein matrix material.
129. The encapsulated or coated stent device of claim 116 further comprising one or more biocompatible polymeric materials.
130. The encapsulated or coated stent device of claim 123 further comprising one or more biocompatible polymeric materials.
131. The encapsulated or coated stent device of claim 128 wherein the one or more biocompatible polymeric materials are selected from the group consisting of epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, polyurethane, polycarbonate, poly(tetrafluoroethylene), polycaprolactone, polyethylene oxide, polyethylene glycol, poly(vinyl chloride), polylactic acid, polyglycolic acid, polypropylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol, 2-hydroxyethyl methacrylate, polymethyl methacrylate, 1,3-bis(carboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxybutyrate, polyhydroxyvalerate, polyethylene oxide), poly ortho esters, poly (amino acids), polycynoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl-based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, and copolymers of these.
132. The encapsulated or coated stent device of claim 129 wherein the one or more biocompatible polymeric materials are selected from the group consisting of epoxies, polyesters, acrylics, nylons, silicones, polyanhydride, polyurethane, polycarbonate, poly(tetrafluoroethylene), polycaprolactone, polyethylene oxide, polyethylene glycol, polyvinyl chloride), polylactic acid, polyglycolic acid, polypropylene oxide, poly(akylene)glycol, polyoxyethylene, sebacic acid, polyvinyl alcohol, 2-hydroxyethyl methacrylate, polymethyl methacrylate, 1,3-bis(caxboxyphenoxy)propane, lipids, phosphatidylcholine, triglycerides, polyhydroxybutyrate, polyhydroxyvalerate, polyethylene oxide), poly ortho esters, poly (amino .
acids), polycynoacrylates, polyphophazenes, polysulfone, polyamine, poly (amido amines), fibrin, graphite, flexible fluoropolymer, isobutyl-based, isopropyl styrene, vinyl pyrrolidone, cellulose acetate dibutyrate, silicone rubber, and copolymers of these.
133. The encapsulated or coated stent device of claim 116 wherein the encapsulated or coated stent device is crosslinked with one or more crosslinking agents.
134. The encapsulated or coated stent device of claim 123 wherein the encapsulated or coated stent device is crosslinked with one or more crosslinking agents.
135. The drug delivery device of claim 58 further comprising a release mechanism that releases the pharmacologically active agent upon contact with an outside stimuli.
136. A protein matrix IUD comprising one or more biocompatible protein materials compressed with one or more biocompatible solvents to remove bulk solvent and form an interacting protein matrix IUD.
137. The protein matrix IUD of claim 135 further including one or more pharmacologically active agents.
138. An image marker comprising one or more biocompatible protein materials compressed with one or more biocompatible solvents to remove bulk solvent and form an interacting image marker.
139. The protein matrix material of claim 17, wherein the matrix material is imprinted by crosslinking in a predetermined pattern utilizing masking or UV light activated reagents.
140. The protein matrix material of claim 18, wherein the matrix material is imprinted by crosslinking in a predetermined pattern utilizing masking or UV light activated reagents.
CA2401385A 2000-02-28 2001-02-28 Protein matrix materials, devices and methods of making and using thereof Expired - Fee Related CA2401385C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18542000P 2000-02-28 2000-02-28
US60/185,420 2000-02-28
US22276200P 2000-08-03 2000-08-03
US60/222,762 2000-08-03
PCT/US2001/006502 WO2001087267A1 (en) 2000-02-28 2001-02-28 Protein matrix materials, devices and methods of making and using thereof

Publications (2)

Publication Number Publication Date
CA2401385A1 true CA2401385A1 (en) 2001-11-22
CA2401385C CA2401385C (en) 2011-05-17

Family

ID=26881122

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2401385A Expired - Fee Related CA2401385C (en) 2000-02-28 2001-02-28 Protein matrix materials, devices and methods of making and using thereof

Country Status (5)

Country Link
EP (1) EP1259223A4 (en)
JP (1) JP2003533468A (en)
AU (2) AU4907901A (en)
CA (1) CA2401385C (en)
WO (1) WO2001087267A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US20050147690A1 (en) * 1998-09-25 2005-07-07 Masters David B. Biocompatible protein particles, particle devices and methods thereof
US20030007991A1 (en) * 1998-09-25 2003-01-09 Masters David B. Devices including protein matrix materials and methods of making and using thereof
US7662409B2 (en) 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
US20020156437A1 (en) * 2000-12-22 2002-10-24 Kimberly-Clark Worldwide, Inc. Removal of targeted proteases with proteinaceous wound dressings containing growth factors
US6444222B1 (en) * 2001-05-08 2002-09-03 Verigen Transplantation Services International Ag Reinforced matrices
CA2457564C (en) 2001-10-05 2009-04-07 Surmodics, Inc. Particle immobilized coatings and uses thereof
US6902932B2 (en) * 2001-11-16 2005-06-07 Tissue Regeneration, Inc. Helically organized silk fibroin fiber bundles for matrices in tissue engineering
ATE310539T1 (en) * 2001-12-21 2005-12-15 Coloplast As ARTICLES FOR WOUND TREATMENT
WO2003092468A2 (en) 2002-04-29 2003-11-13 Gel-Del Technologies, Inc. Biomatrix structural containment and fixation systems and methods of use thereof
EP1545505A4 (en) * 2002-08-02 2008-01-02 Gp Medical Drug-loaded biological material chemically treated with genipin
US20040121009A1 (en) * 2002-10-17 2004-06-24 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
WO2004043509A1 (en) * 2002-11-08 2004-05-27 Conor Medsystems, Inc. Expandable medical device and method for treating chronic total occlusions with local delivery of an angiogenic factor
EP1918301A1 (en) * 2003-03-28 2008-05-07 Fuji Film Manufacturing Europe B.V. RGD-enriched gelatine-like proteins for inhibition of cancer metastasis
JP4850709B2 (en) * 2003-05-14 2012-01-11 ダニスコ・ユーエス・インコーポレーテッド Controlled release of active agent using repetitive sequence protein polymer
US8465537B2 (en) 2003-06-17 2013-06-18 Gel-Del Technologies, Inc. Encapsulated or coated stent systems
US8734421B2 (en) 2003-06-30 2014-05-27 Johnson & Johnson Consumer Companies, Inc. Methods of treating pores on the skin with electricity
EP1660013A4 (en) * 2003-08-26 2011-07-20 Gel Del Technologies Inc Protein biomaterials and biocoacervates and methods of making and using thereof
AU2004296851A1 (en) 2003-12-08 2005-06-23 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
KR20070009565A (en) * 2004-01-23 2007-01-18 캘리포니아 인스티튜트 오브 테크놀로지 Engineered proteins, and methods of making and using
US8178656B2 (en) 2004-06-11 2012-05-15 Trustees Of Tufts College Silk-based drug delivery system
US20060067971A1 (en) * 2004-09-27 2006-03-30 Story Brooks J Bone void filler
DK1986611T3 (en) * 2006-02-23 2013-07-29 Danisco Us Inc Protein polymer nanoparticles with repeat sequence possibly containing active substances and preparation thereof
US20070219585A1 (en) * 2006-03-14 2007-09-20 Cornet Douglas A System for administering reduced pressure treatment having a manifold with a primary flow passage and a blockage prevention member
CA2711001A1 (en) 2007-12-26 2009-07-09 Gel-Del Technologies, Inc. Biocompatible protein-based particles and methods thereof
CN101221180B (en) * 2008-01-25 2011-11-30 马义才 Portable fast joint inspection device for multiple tumor marker
WO2010026760A1 (en) * 2008-09-03 2010-03-11 富士フイルム株式会社 Compositions wherein bioactive components are stably sealed
WO2010057177A2 (en) 2008-11-17 2010-05-20 Gel-Del Technologies, Inc. Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
US9308070B2 (en) 2008-12-15 2016-04-12 Allergan, Inc. Pliable silk medical device
US20110060419A1 (en) * 2009-03-27 2011-03-10 Jennifer Hagyoung Kang Choi Medical devices with galvanic particulates
JP2012528149A (en) 2009-05-28 2012-11-12 アドビオ・アーベー Multilayer protein film, method for producing the film, and drug delivery device and medical implant using the film
CA2890372A1 (en) 2011-11-09 2013-05-16 Trustees Of Tufts College Injectable silk fibroin foams and uses thereof
JP2015510818A (en) * 2012-03-20 2015-04-13 トラスティーズ オブ タフツ カレッジ Silk reservoir for drug delivery
JP6283655B2 (en) 2012-03-29 2018-02-21 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド Ionizable cationic lipid
US8691915B2 (en) 2012-04-23 2014-04-08 Sabic Innovative Plastics Ip B.V. Copolymers and polymer blends having improved refractive indices
US11617815B2 (en) 2016-10-31 2023-04-04 Sofregen Medical, Inc. Compositions comprising silk fibroin particles and uses thereof
CN108310455B (en) * 2018-03-20 2021-07-30 嘉兴尔云信息科技有限公司 Nano hydroxyapatite and PGS-M composite bone repair material and preparation method thereof
CN108926744A (en) * 2018-09-13 2018-12-04 广州贝奥吉因生物科技有限公司 A kind of compound rest and preparation method thereof for repair of cartilage
US11738174B2 (en) 2019-10-15 2023-08-29 Sofregen Medical, Inc. Delivery devices for delivering and methods of delivering compositions
TWI763265B (en) * 2021-01-20 2022-05-01 巴斯特製藥科技顧問股份有限公司 An organ-repairing membrane with structural proteins and use thereof
CN114354585B (en) * 2021-11-09 2023-09-26 北京航空航天大学 Horseradish peroxidase composite gel photonic crystal sensor and method
CN114505070B (en) * 2022-04-02 2024-02-02 陕西师范大学 Porous nano-enzyme, porous nano-enzyme crystal, preparation method and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
AU8702491A (en) * 1990-11-08 1992-05-14 Matrix Pharmaceutical, Inc. Fibrin/collagen membrane material for biomedical use
JPH06500802A (en) * 1991-06-14 1994-01-27 アムジエン・インコーポレーテツド Protein drug delivery using collagen film
WO1993021226A1 (en) * 1992-04-10 1993-10-28 The General Hospital Corporation Cartilage matrix protein and methods for use
AU7568394A (en) * 1993-08-19 1995-03-14 Cygnus Therapeutic Systems Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
US5783214A (en) * 1994-06-13 1998-07-21 Buford Biomedical, Inc. Bio-erodible matrix for the controlled release of medicinals
CN1052915C (en) * 1995-11-27 2000-05-31 中国医学科学院生物医学工程研究所 Medical carrier of protein coat for carrying gene and its prodn. method
WO1997041899A1 (en) * 1996-05-03 1997-11-13 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
US6221425B1 (en) * 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
GB9806966D0 (en) * 1998-03-31 1998-06-03 Ppl Therapeutics Scotland Ltd Bioloically modified device
US6544548B1 (en) * 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
JP4332660B2 (en) * 1999-10-01 2009-09-16 Ｏｃｉ株式会社 Mouth cool film

Also Published As

Publication number Publication date
AU2001249079B2 (en) 2005-11-03
EP1259223A4 (en) 2006-11-29
JP2003533468A (en) 2003-11-11
AU4907901A (en) 2001-11-26
WO2001087267A1 (en) 2001-11-22
CA2401385C (en) 2011-05-17
EP1259223A1 (en) 2002-11-27

Similar Documents

Publication Publication Date Title
CA2401385A1 (en) Protein matrix materials, devices and methods of making and using thereof
JP2003533468A5 (en)
Choi et al. Study on gelatin-containing artificial skin: I. Preparation and characteristics of novel gelatin-alginate sponge
EP0888140B1 (en) Coated bioabsorbable beads for wound treatment
EP0701802B1 (en) Drug eluting stent
Shin et al. In vivo bone and soft tissue response to injectable, biodegradable oligo (poly (ethylene glycol) fumarate) hydrogels
Panduranga Rao Recent developments of collagen-based materials for medical applications and drug delivery systems
US8871267B2 (en) Protein matrix materials, devices and methods of making and using thereof
US5358475A (en) High molecular weight bioresorbable polymers and implantable devices thereof
EP1773242B1 (en) Encapsulated or coated stent systems
US20100318108A1 (en) Composite mesh devices and methods for soft tissue repair
US20030133967A1 (en) Multilayer collagen matrix for tissue reconstruction
EP1208818A2 (en) Mold for making an intralumimal stent
US20050043814A1 (en) Acellular matrix implanted into an articular cartilage or osteochondral lesion protected with a biodegradable polymer modified to have extended polymerization time and methods for preparation and use thereof
US20120282300A1 (en) Protein biomaterials and biocoacervates and methods of making and using thereof
EP1656081A2 (en) Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and a method for use thereof
JP2005329264A (en) Composition to form interpenetrating polymer network structure for using it as high-strength medical sealant
AU2001249079A1 (en) Protein matrix materials, devices and methods of making and using thereof
EP1253857A1 (en) Device for the closure of a surgical puncture
US20100125330A1 (en) Synthetic vascular prosthesis and method of preparation
Gorham et al. The in vitro assessment of a collagen/vicryl (polyglactin) composite film together with candidate suture materials for use in urinary tract surgery: I. Physical testing
JPWO2009122710A1 (en) Medical composition
JP2001212222A (en) Wound coating material
San Román et al. Contribution of polymeric supports to the development of tissue engineering
AU2004279349B2 (en) Protein biomaterials and biocoacervates and methods of making and using thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170228